Sunday - May 4, 2025
PLANO, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) announced today that it plans to release financial and operational results for first quarter 2024, at 7 a.m. Central Time (CT) / 8 a.m. Eastern Time (ET) on Thursday, April 25, 2024. Following the release, Integer management will host a webcast at 8 a.m. CT / 9 a.m. ET to discuss these results. Other forward-looking and material information may also be discussed during this call.
Conference call details:
An audio replay will be available for seven days and can be accessed by dialing (800) 770-2030 or (609) 800-9909 and using Conference ID 9252310. The conference call will also be available live or via archived replay on the Investor Relations section of the Integer website at: investor.integer.net.
From time to time, the Company posts information that may be of interest to investors on its website at investor.integer.net. To automatically receive Integer financial news by email, please visit investor.integer.net and subscribe to email alerts.
About Integer®
Integer Holdings Corporation (NYSE:ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMO) in the world, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. As a strategic partner of choice to medical device companies and OEMs, the Company is committed to enhancing the lives of patients worldwide by providing innovative, high-quality products and solutions. The Company's brands include Greatbatch Medical®, Lake Region Medical® and Electrochem®. Additional information is available at www.integer.net.
Investor Relations: | Media Relations: |
Andrew Senn | Kelly Butler |
andrew.senn@integer.net | kelly.butler@integer.net |
763.951.8312 | 214.618.4216 |
Last Trade: | US$125.66 |
Daily Change: | 0.07 0.06 |
Daily Volume: | 635,012 |
Market Cap: | US$4.210B |
April 24, 2025 April 24, 2025 March 18, 2025 March 12, 2025 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load